Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The complement C3a/C3aR pathway is associated with treatment resistance to gemcitabine-based neoadjuvant therapy in pancreatic cancer

4 Oct 2024

Abstract excerpt

Gemcitabine is a standard first-line drug for pancreatic cancer chemotherapy. Nevertheless, gemcitabine resistance is common and significantly limits its therapeutic efficacy, impeding advancements in pancreatic cancer treatment. In this study, through a comprehensive analysis of gemcitabine-resistant cell lines and patient samples, 39 gemcitabine resistance-associated risk genes were identified, and two distinct...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Complement system in diseases
Share to Neuroendocrine Tumor Research Advances
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39469671
DOI: 10.1016/j.csbj.2024.09.032

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The complement C3a/C3aR pathway is associated with treatment resistance to gemcitabine-based neoadjuvant therapy in pancreatic cancerPMID 39469671Read ↗

Overcoming drug resistance in pancreatic cancer.Semantic proximity Read ↗

Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft ModelsSemantic proximity Read ↗

A 14-gene gemcitabine resistance gene signature is significantly associated with the prognosis of pancreatic cancer patientsSemantic proximity Read ↗

Multidrug resistance genes screening of pancreatic cancer based on sensitivity profile to chemotherapeutic drugsSemantic proximity Read ↗

Noncoding RNAs in drug-resistant pancreatic cancer: A reviewSemantic proximity Read ↗

GSK2126458 has the potential to inhibit the proliferation of pancreatic cancer uncovered by bioinformatics analysis and pharmacological experimentsSemantic proximity Read ↗

Inhibition of the Complement Pathway Induces Cellular Proliferation and Migration in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

MicroRNAs in pancreatic cancer drug resistance: mechanisms and therapeutic potentialSemantic proximity Read ↗

Identification of chemoresistance‐related mRNAs based on gemcitabine‐resistant pancreatic cancer cell linesSemantic proximity Read ↗

Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures.Semantic proximity Read ↗

Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancerSemantic proximity Read ↗

MicroRNA-gene signaling pathways in pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.